Microcephaly 6, primary, autosomal recessive
diseaseOn this page
Also known as autosomal recessive primary microcephaly caused by mutation in CENPJCENPJ autosomal recessive primary microcephalyMCPH6
Summary
Microcephaly 6, primary, autosomal recessive (MONDO:0012029) is a disease caused by CPAP (GenCC Definitive), with 2 cohort genes.
At a glance
- Causal gene: CPAP (GenCC Definitive)
- Cohort genes: 2
- ClinVar variants: 154
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | microcephaly 6, primary, autosomal recessive |
| Mondo ID | MONDO:0012029 |
| MeSH | C564247 |
| OMIM | 608393 |
| DOID | DOID:0070290 |
| UMLS | C1842109 |
| MedGen | 330770 |
| GARD | 0015431 |
| Is cancer (heuristic) | no |
Also known as: autosomal recessive primary microcephaly caused by mutation in CENPJ · CENPJ autosomal recessive primary microcephaly · MCPH6 · microcephaly 6, primary, autosomal recessive
Data availability: 154 ClinVar variants · 2 GenCC gene-disease records.
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary disease › autosomal genetic disease › autosomal recessive disease › autosomal recessive primary microcephaly › microcephaly with or without short stature › microcephaly 6 with or without short stature › microcephaly 6, primary, autosomal recessive
Related subtypes (1): Seckel syndrome 4
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
ClinVar germline variants
154 retrieved; paginated sample, class counts are floors:
71 uncertain significance, 31 conflicting classifications of pathogenicity, 15 benign, 10 pathogenic, 10 pathogenic/likely pathogenic, 9 benign/likely benign, 7 likely pathogenic, 1 not provided
| ClinVar | Variant (HGVS) | Gene | Classification | Review |
|---|---|---|---|---|
| 1032802 | NM_018451.5(CPAP):c.2117_2118del (p.Asp705_Ser706insTer) | CPAP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 158194 | NM_018451.5(CPAP):c.1586C>G (p.Ser529Ter) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1676662 | NM_018451.5(CPAP):c.2863G>T (p.Glu955Ter) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1817 | NM_018451.5(CPAP):c.18del (p.Ser7fs) | CPAP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 1818 | NM_018451.5(CPAP):c.3704A>T (p.Glu1235Val) | CPAP | Pathogenic | no assertion criteria provided |
| 1819 | NM_018451.5(CPAP):c.3243_3246del (p.Ser1081fs) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 210661 | NM_018451.5(CPAP):c.1969C>T (p.Gln657Ter) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 2429273 | NM_018451.5(CPAP):c.505_506del (p.Gln169fs) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 279750 | NM_018451.5(CPAP):c.289dup (p.Thr97fs) | CPAP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 280184 | NM_018451.5(CPAP):c.1696C>T (p.Arg566Ter) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 280927 | NM_018451.5(CPAP):c.40C>T (p.Gln14Ter) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 432139 | NM_018451.5(CPAP):c.2872C>T (p.Arg958Ter) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 4688175 | NM_018451.5(CPAP):c.3398_3399del (p.Leu1133fs) | CPAP | Pathogenic | criteria provided, single submitter |
| 496762 | NM_018451.5(CPAP):c.3586G>A (p.Asp1196Asn) | CPAP | Pathogenic | no assertion criteria provided |
| 496814 | NM_018451.5(CPAP):c.59G>A (p.Trp20Ter) | CPAP | Pathogenic | no assertion criteria provided |
| 503611 | NM_018451.5(CPAP):c.1132C>T (p.Arg378Ter) | CPAP | Pathogenic | criteria provided, multiple submitters, no conflicts |
| 620160 | NM_018451.5(CPAP):c.634G>T (p.Glu212Ter) | CPAP | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 158211 | NM_018451.5(CPAP):c.3448C>T (p.Gln1150Ter) | RNF17 | Pathogenic | criteria provided, single submitter |
| 18417 | NM_018451.5(CPAP):c.3302-1G>C | RNF17 | Pathogenic | criteria provided, single submitter |
| 1975927 | NM_018451.5(CPAP):c.3673del (p.Glu1225fs) | RNF17 | Pathogenic/Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 1679845 | NM_018451.5(CPAP):c.265_266del (p.Gln89fs) | CPAP | Likely pathogenic | criteria provided, single submitter |
| 4294006 | NM_018451.5(CPAP):c.3673dup (p.Glu1225fs) | CPAP | Likely pathogenic | criteria provided, single submitter |
| 4819892 | NM_018451.5(CPAP):c.422del (p.Pro141fs) | CPAP | Likely pathogenic | criteria provided, single submitter |
| 4845881 | NM_018451.5(CPAP):c.723_734delinsC (p.Gln241fs) | CPAP | Likely pathogenic | criteria provided, single submitter |
| 522642 | NM_018451.5(CPAP):c.3893G>A (p.Arg1298Gln) | CPAP | Likely pathogenic | criteria provided, single submitter |
| 977853 | NM_018451.5(CPAP):c.1426C>T (p.Gln476Ter) | CPAP | Likely pathogenic | no assertion criteria provided |
| 417856 | NM_018451.5(CPAP):c.3367-1G>A | RNF17 | Likely pathogenic | criteria provided, multiple submitters, no conflicts |
| 158192 | NM_018451.5(CPAP):c.1410G>A (p.Pro470=) | CPAP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 158193 | NM_018451.5(CPAP):c.1513G>A (p.Glu505Lys) | CPAP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
| 158196 | NM_018451.5(CPAP):c.175A>G (p.Thr59Ala) | CPAP | Conflicting classifications of pathogenicity | criteria provided, conflicting classifications |
Genes & proteins
Mendelian disease overlap and somatic drivers
GenCC: 5 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0
GenCC gene–disease validity (cohort genes)
the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.
| Gene | Classification | Inheritance | Disease | Records |
|---|---|---|---|---|
| CPAP | Definitive | Autosomal recessive | microcephaly 6 with or without short stature | 5 |
Orphanet rare-disease linkage (cohort genes)
| Gene | Orphanet ID | Rare disease |
|---|---|---|
| CPAP | Orphanet:2512 | Autosomal recessive primary microcephaly |
| CPAP | Orphanet:808 | Seckel syndrome |
Cohort genes → proteins
2 cohort genes, 2 distinct canonical proteins.
Evidence partition
| Subset | Genes |
|---|---|
| multi_evidence | 2 |
Cohort genes (full)
| Symbol | HGNC | Ensembl | UniProt | Name | Evidence |
|---|---|---|---|---|---|
| CPAP | HGNC:17272 | ENSG00000151849 | Q9HC77 | Centrosomal P4.1-associated protein | gencc,clinvar |
| RNF17 | HGNC:10060 | ENSG00000132972 | Q9BXT8 | RING finger protein 17 | clinvar |
Cohort function summary
Lead sentence per gene, UniProt-curated.
| Symbol | Protein name | Function (lead sentence) |
|---|---|---|
| CPAP | Centrosomal P4.1-associated protein | Plays an important role in cell division and centrosome function by participating in centriole duplication. |
| RNF17 | RING finger protein 17 | Seems to be involved in regulation of transcriptional activity of MYC. |
Protein-family classification
Druggable: 0 · Difficult: 1 · Unknown: 1 · Druggable fraction: 0.0
Family distribution
Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.
| Family | Genes | Fold | FDR |
|---|---|---|---|
| Transcription factor | 1 | 4.1× | 0.455 |
| Other/Unknown | 1 | 0.9× | 0.805 |
Per-gene assignment
| Symbol | Family | Druggable? | EC | InterPro (top 3) |
|---|---|---|---|---|
| CPAP | Other/Unknown | no | CENPJ_C_dom, TCP10L/CENPJ, Tcp10_C_sf | |
| RNF17 | Transcription factor | no | Znf_RING, Tudor, Znf_RING_CS |
Expression context
Cohort genes with no expression data: 0.
2 cohort genes are a single-cell marker in ≥1 SCXA experiment.
Breadth distribution (Bgee present_calls)
| Bucket | Genes |
|---|---|
| narrow (1-5 tissues) | 0 |
| moderate (6-20) | 0 |
| broad (>20) | 2 |
| unknown | 0 |
Top tissues across cohort
| Tissue | Cohort genes |
|---|---|
| left lobe of thyroid gland | 1 |
| right lobe of thyroid gland | 1 |
| sperm | 1 |
| male germ line stem cell (sensu Vertebrata) in testis | 1 |
| primordial germ cell in gonad | 1 |
| right testis | 1 |
Per-gene tissue summary (top 30)
| Symbol | Bgee breadth | FANTOM5 breadth | SCXA | Top tissues |
|---|---|---|---|---|
| CPAP | 246 | ubiquitous | marker | sperm, left lobe of thyroid gland, right lobe of thyroid gland |
| RNF17 | 142 | tissue_specific | marker | male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad, right testis |
Protein interactions among cohort
Intra-cohort edges: 0.
Hub genes (top 10 by interactor count)
| Symbol | Interactor count |
|---|---|
| CPAP | 2,242 |
| RNF17 | 1,108 |
Structural data
PDB: 2 · AlphaFold-only: 0 · No structure: 0
Cohort genes with PDB structures (top 30)
| Symbol | UniProt | PDB entries |
|---|---|---|
| CPAP | Q9HC77 | 6 |
| RNF17 | Q9BXT8 | 1 |
Function
Pathway analysis
Distinct Reactome pathways touched by cohort: 8. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).
Pathways by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| Pathway | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | 1 | 519.1× | 0.009 | CPAP |
| Loss of Nlp from mitotic centrosomes | 1 | 158.6× | 0.009 | CPAP |
| Loss of proteins required for interphase microtubule organization from the centrosome | 1 | 158.6× | 0.009 | CPAP |
| AURKA Activation by TPX2 | 1 | 152.3× | 0.009 | CPAP |
| Recruitment of mitotic centrosome proteins and complexes | 1 | 135.9× | 0.009 | CPAP |
| Regulation of PLK1 Activity at G2/M Transition | 1 | 126.9× | 0.009 | CPAP |
| Recruitment of NuMA to mitotic centrosomes | 1 | 116.5× | 0.009 | CPAP |
| Anchoring of the basal body to the plasma membrane | 1 | 113.1× | 0.009 | CPAP |
GO biological processes by enrichment
Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.
| GO term | Cohort genes | Fold | FDR | Sample cohort genes |
|---|---|---|---|---|
| astral microtubule nucleation | 1 | 8426.0× | 0.002 | CPAP |
| centriole elongation | 1 | 2106.5× | 0.003 | CPAP |
| positive regulation of centriole replication | 1 | 1685.2× | 0.003 | CPAP |
| positive regulation of establishment of protein localization | 1 | 1404.3× | 0.003 | CPAP |
| positive regulation of centriole elongation | 1 | 1203.7× | 0.003 | CPAP |
| positive regulation of spindle assembly | 1 | 1053.2× | 0.003 | CPAP |
| positive regulation of non-motile cilium assembly | 1 | 936.2× | 0.003 | CPAP |
| regulation of centriole replication | 1 | 842.6× | 0.003 | CPAP |
| microtubule polymerization | 1 | 443.5× | 0.005 | CPAP |
| regulation of mitotic spindle organization | 1 | 421.3× | 0.005 | CPAP |
| centriole replication | 1 | 366.4× | 0.005 | CPAP |
| microtubule nucleation | 1 | 312.1× | 0.005 | CPAP |
| motile cilium assembly | 1 | 290.6× | 0.005 | CPAP |
| positive regulation of receptor signaling pathway via JAK-STAT | 1 | 216.1× | 0.007 | CPAP |
| positive regulation of G1/S transition of mitotic cell cycle | 1 | 200.6× | 0.007 | CPAP |
| non-motile cilium assembly | 1 | 145.3× | 0.009 | CPAP |
| smoothened signaling pathway | 1 | 90.6× | 0.013 | CPAP |
| spermatid development | 1 | 72.6× | 0.015 | RNF17 |
| cilium assembly | 1 | 36.8× | 0.028 | CPAP |
| cell division | 1 | 23.1× | 0.043 | CPAP |
Therapeutics
Drug target analysis
Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 2
Druggability breadth: 0 of 2 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).
Top cohort targets by molecule count
| Symbol | Molecules | Max phase |
|---|---|---|
| CPAP | 0 | 0 |
| RNF17 | 0 | 0 |
Bioactivity and enzyme data
Enzyme cohort genes (≥1 EC): 0.
Pharmacogenomics
Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.
No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).
Chemical tractability of cohort targets
0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.
Druggability pyramid
Cohort genes binned by druggability tier (high → low):
| Tier | Definition | Genes | Symbols |
|---|---|---|---|
| A | Approved (phase 4 drug) | 0 | |
| B | Phased (≥1) drug, not yet approved | 0 | |
| C | Druggable family + PDB, no drug | 0 | |
| D | Druggable family + AlphaFold only, no drug | 0 | |
| E | Difficult family or no structure, no drug | 2 | CPAP, RNF17 |
Undrugged target profiles
2 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).
| Symbol | ChEMBL assays | Drugged partners (top 3) |
|---|---|---|
| CPAP | 0 | — |
| RNF17 | 0 | — |
Clinical trials & evidence
Clinical trials
Clinical trials: 0.